Physician profile
Michael C Chapman
NPI 1063735900
$654.18
in general payments reported to CMS, 2019-2025
15 companies · $153 in 2025
The $153 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.43 · 2021: $55.27 · 2022: $77.52 · 2023: $82.21 · 2024: $242 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $201.23 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $99.69 | 2024 | |
| Cranial Technologies, INC | $68.73 | 2019-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $65.46 | 2025 | Jornay Pm |
| Pfizer INC. | $41.46 | 2019-2022 | |
| Baxter Healthcare | $24.13 | 2022 | |
| Welch Allyn | $24.13 | 2021 | |
| Sanofi Pasteur INC. | $23.36 | 2023 | |
| Merck Sharp & Dohme LLC | $18.39 | 2021 | |
| Kaleo, INC. | $16.83 | 2023 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $15.57 | 2023 | Qelbree |
| Nestle Healthcare Nutrition INC. | $15.02 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.02 | 2025 | Alvesco |
| Sobi, INC | $13.32 | 2019 | |
| Phadia US INC. | $12.84 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.